Literature DB >> 26511077

Psychological distress in Rome III functional dyspepsia patients presenting for testing of gastric emptying.

J K Dibaise1, R S Islam1, A C Dueck2, M C Roarke3, M D Crowell1.   

Abstract

BACKGROUND: There have been conflicting results from studies that have evaluated psychological disturbances in functional dyspepsia (FD). We conducted a comprehensive survey of psychological measures in patients undergoing gastric emptying testing (GET) in order to determine the relationship among psychological distress, gastric emptying, and dyspeptic symptoms.
METHODS: Consecutive patients referred for GET were prospectively enrolled. Details regarding patient characteristics, health care utilization, dyspeptic symptoms, quality of life, and psychological dysfunction were obtained. Depression, anxiety, somatization, stress, positive and negative affect, and alexithymia were queried using validated questionnaires. We compared those dyspeptic patients who met Rome III criteria for FD to those who did not meet these criteria. KEY
RESULTS: Two hundred and nine patients (160 female; mean age 46.6 years ± 17.3 years) participated. Around 151 patients (72%) met Rome III criteria for FD. In the entire group, a high level of depression, anxiety, somatization, and perceived stress was present compared to population norms. Health care seeking behavior and symptom severity were greater in those with FD and quality of life was lower compared to non-FD. Gastric emptying did not differentiate the two groups and similar degrees of psychological distress were present whether emptying was delayed or normal. CONCLUSIONS & INFERENCES: In patients referred for GET, substantial psychological distress is present. The degree of distress was similar regardless of whether the patient met Rome III FD criteria or not. Further evaluation of psychological dysfunction in FD patients may lead to improved diagnosis and determination of the most appropriate treatment.
© 2015 John Wiley & Sons Ltd.

Entities:  

Keywords:  alexithymia; anxiety; depression; functional dyspepsia; gastroparesis; positive/negative affect; somatization; stress

Mesh:

Year:  2015        PMID: 26511077     DOI: 10.1111/nmo.12709

Source DB:  PubMed          Journal:  Neurogastroenterol Motil        ISSN: 1350-1925            Impact factor:   3.598


  6 in total

Review 1.  Chronic Unexplained Nausea and Vomiting or Gastric Neuromuscular Dysfunction (GND)? An Update on Nomenclature, Pathophysiology and Treatment, and Relationship to Gastroparesis.

Authors:  Kimberly N Harer; Pankaj J Pasricha
Journal:  Curr Treat Options Gastroenterol       Date:  2016-12

2.  Trends and Socioeconomic Health Outcomes of Cannabis Use Among Patients With Gastroparesis: A United States Nationwide Inpatient Sample Analysis.

Authors:  Thomas R McCarty; Fouad Chouairi; Kelly E Hathorn; Walter W Chan; Christopher C Thompson
Journal:  J Clin Gastroenterol       Date:  2022-04-01       Impact factor: 3.062

3.  Changes in patients' symptoms and gastric emptying after Helicobacter pylori treatment.

Authors:  Chun-Ling Zhang; Chang-Hui Geng; Zhi-Wei Yang; Yan-Lin Li; Li-Quan Tong; Ping Gao; Yue-Qiu Gao
Journal:  World J Gastroenterol       Date:  2016-05-14       Impact factor: 5.742

4.  Alexithymia in Gastroenterology and Hepatology: A Systematic Review.

Authors:  Danilo Carrozzino; Piero Porcelli
Journal:  Front Psychol       Date:  2018-04-06

Review 5.  Functional Dyspepsia: A Narrative Review With a Focus on Sex-Gender Differences.

Authors:  Young Sun Kim; Nayoung Kim
Journal:  J Neurogastroenterol Motil       Date:  2020-07-30       Impact factor: 4.924

6.  99mTc-sodium phytate is a valid alternative to the gold-standard 99mTc-sulfur colloid in the measurement of gastric emptying among healthy multi-ethnic Asian population: results of a randomized cross-over trial.

Authors:  Norazlina Mat Nawi; Nashrulhaq Tagiling; Mohd Fazrin Mohd Rohani; Wan Mohd Nazlee Wan Zainon; Muhammad Saifuddin Zanial; Mung Seong Wong; Yeong Yeh Lee
Journal:  BMC Gastroenterol       Date:  2020-08-31       Impact factor: 3.067

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.